当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.

Abstract：

:Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3'-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.

journal_name

Leukemia

journal_title

Leukemia

authors

Kataoka K,Miyoshi H,Sakata S,Dobashi A,Couronné L,Kogure Y,Sato Y,Nishida K,Gion Y,Shiraishi Y,Tanaka H,Chiba K,Watatani Y,Kakiuchi N,Shiozawa Y,Yoshizato T,Yoshida K,Makishima H,Sanada M,Onozawa M,Teshima T,Yos

doi

10.1038/s41375-019-0380-5

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

1687-1699

issue

7

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-019-0380-5

journal_volume

33

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients.

    abstract：:A prospective, randomized double-blind study comparing the effects of irradiated and unirradiated white blood cells was conducted in 108 acute leukemia patients with life-threatening infections, refractory to antibiotics. The study demonstrated no significant improvement in 30-day survival or overall survival. Transfu...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/leu.2012.301

    authors： Freireich EJ,Lichtiger B,Mattiuzzi G,Martinez F,Reddy V,Kyle Wathen J

    更新日期：2013-04-01 00:00:00

  • Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.

    abstract：:Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.176

    authors： Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum FR,Estey E

    更新日期：2014-02-01 00:00:00

  • Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

    abstract：:This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.173

    authors： Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

    更新日期：2017-12-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract：:Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.260

    authors： Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期：2017-03-01 00:00:00

  • Prognostic value of residual normal metaphases in acute myelogenous leukemia patients presenting with abnormal karyotype.

    abstract：:Two hundred and forty-four untreated acute myelogenous leukemia (AML) patients with unfavorable karyotypes and 109 others with favorable aneuploid karyotypes were used to evaluate the prognostic significance of having both normal and abnormal metaphases (AN) vs only abnormal metaphases (AA) at AML presentation. The AA...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Ghaddar HM,Pierce S,Reed P,Estey EH

    更新日期：1995-05-01 00:00:00

  • Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.

    abstract：:Despite recent advances in our understanding of the molecular and biological abnormalities in chronic myelogenous leukemia (CML) this new knowledge has not yet led to significant improvements in treatment. We have reviewed what is known and still unknown about the molecular and biological abnormalities in CML that may...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Clarkson B,Strife A

    更新日期：1993-11-01 00:00:00

  • Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas.

    abstract：:Germline CD95 (also known as FAS, APT1 and APO1) gene mutations have been associated with benign lymphoproliferative diseases and autoimmune processes. Somatic mutations have been reported in human tumours, including lymphomas. Since marginal zone B cell lymphomas usually arise in a background of chronic inflammation,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401708

    authors： Bertoni F,Conconi A,Luminari S,Realini C,Roggero E,Baldini L,Carobbio S,Cavalli F,Neri A,Zucca E

    更新日期：2000-03-01 00:00:00

  • Deletions on der(9) chromosome in adult Ph-positive acute lymphoblastic leukemia occur with a frequency similar to that observed in chronic myeloid leukemia.

    abstract：:The t(9;22)(q34;q11), generating the Philadelphia chromosome (Ph), is found in more than 90% of patients with chronic myeloid leukemia (CML) and in 15-30% of adults with acute lymphoblastic leukemia (ALL). Different groups have recently described the presence of large genomic deletions adjacent to the translocation br...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402829

    authors： Specchia G,Albano F,Anelli L,Storlazzi CT,Zagaria A,Mancini M,Cuneo A,Pane F,Foà R,Manolelli F,Liso V,Rocchi M

    更新日期：2003-03-01 00:00:00

  • The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice.

    abstract：:Hematopoietic stem cells are identified based on their functional ability to migrate via the blood circulation of transplanted recipients, to home to the host bone marrow and to durably repopulate this organ with high levels of maturing myeloid and lymphoid cells. While a small pool of undifferentiated stem cells with...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2402684

    authors： Lapidot T,Kollet O

    更新日期：2002-10-01 00:00:00

  • Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.

    abstract：:These ECOG trials have demonstrated that progressive increments in the intensity of post-remission therapy result in improving long-term, disease-free survival in adults with AML. The median duration of disease-free survival and long-term outcome from different post-remission therapies are summarized in Table 4. [tabl...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Cassileth PA,Andersen JW,Bennett JM,Harrington DP,Hines JD,Lazarus HM,Mazza JJ,McGlave PP,O'Connell MJ,Paietta E

    更新日期：1992-01-01 00:00:00

  • Expression of p16INK4A and p14ARF in hematological malignancies.

    abstract：:The INK4A/ARF locus yields two tumor suppressors, p16INK4A and p14ARF, and is frequently deleted in human tumors. We studied their mRNA expressions in 41 hematopoietic cell lines and in 137 patients with hematological malignancies; we used a quantitative reverse transcription-PCR assay. Normal peripheral bloods, bone ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401557

    authors： Taniguchi T,Chikatsu N,Takahashi S,Fujita A,Uchimaru K,Asano S,Fujita T,Motokura T

    更新日期：1999-11-01 00:00:00

  • Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations.

    abstract：:Children with Down's syndrome (DS) have an increased risk of developing acute lymphoblastic leukemia (ALL) and have a low frequency of established genetic aberrations. We aimed to determine which genetic abnormalities are involved in DS ALL. We studied the frequency and prognostic value of deletions in B-cell developm...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.84

    authors： Buitenkamp TD,Pieters R,Gallimore NE,van der Veer A,Meijerink JP,Beverloo HB,Zimmermann M,de Haas V,Richards SM,Vora AJ,Mitchell CD,Russell LJ,Schwab C,Harrison CJ,Moorman AV,van den Heuvel-Eibrink MM,den Boer ML,Zwaan

    更新日期：2012-10-01 00:00:00

  • Is the mdr 1 gene relevant in chronic lymphocytic leukemia?

    abstract：:Chronic lymphocytic leukemia (CLL) is a progressive disease in which chemotherapy may result in temporary suppression of the peripheral blood lymphocyte count, but cure is not usually possible. Drug resistance mechanisms and the multidrug resistant (MDR) phenotype may be relevant to the therapeutic response. We have s...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Holmes JA,Jacobs A,Carter G,Whittaker JA,Bentley DP,Padua RA

    更新日期：1990-03-01 00:00:00

  • Isolation and characterization of c-fos-expressing murine bone marrow stromal cell lines supporting myeloid differentiation.

    abstract：:We have previously reported that constitutive expression of c-fos oncogene allows long-term proliferation of primary mouse bone marrow stromal cells favoring the granulocytic differentiation of myeloid precursors in an in vitro assay. Retrovirus-mediated gene transfer of the human c-fos gene was used here for immortal...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Steff AM,Bouaboula M,Mouchiroud G,Arnaud S,Roux P,Cassellas P,Piechaczyk M

    更新日期：1996-03-01 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract：:The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402150

    authors： Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期：2001-08-01 00:00:00

  • Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

    abstract：:Smoldering multiple myeloma (SMM) is a biologically heterogeneous, clinically defined entity with a variable rate of progression to symptomatic multiple myeloma (MM). Reliable markers for progression are critical for the development of potential therapeutic interventions. We retrospectively evaluated the predictive va...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0013-4

    authors： Fernández de Larrea C,Isola I,Pereira A,Cibeira MT,Magnano L,Tovar N,Rodríguez-Lobato LG,Calvo X,Aróstegui JI,Díaz T,Lozano E,Rozman M,Yagüe J,Bladé J,Rosiñol L

    更新日期：2018-06-01 00:00:00

  • Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

    abstract：:Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/s41375-020-0718-z

    authors： Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CC

    更新日期：2020-07-01 00:00:00

  • Identification of a gene element essential for leukemia-specific expression of transgenes.

    abstract：:Leukemia-specific promoters and enhancers for gene therapy had never been reported. Since the Wilms' tumor gene WT1 is overexpressed in almost all types of leukemia, WT1 is an ideal target of leukemia-specific therapy. To explore the possibility of gene therapy for leukemia using WT1 promoter and enhancer, their activ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403260

    authors： Hosen N,Yanagihara M,Nakazawa T,Kanato K,Nishida S,Shirakata T,Asada M,Masuda T,Taniguchi Y,Kawakami M,Tsuboi A,Ikegame K,Oka Y,Ogawa H,Kawase I,Oji Y,Sugiyama H

    更新日期：2004-03-01 00:00:00

  • High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

    abstract：:Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are largely undefined. T...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.105

    authors： Metzelder SK,Schroeder T,Finck A,Scholl S,Fey M,Götze K,Linn YC,Kröger M,Reiter A,Salih HR,Heinicke T,Stuhlmann R,Müller L,Giagounidis A,Meyer RG,Brugger W,Vöhringer M,Dreger P,Mori M,Basara N,Schäfer-Eckart K,S

    更新日期：2012-11-01 00:00:00

  • Rapid positive selection of CD34+ cells using magnetic microspheres coated with monoclonal antibody QBEND/10 linked via a cleavable disulphide bond.

    abstract：:Positive selection of CD34+ cells has applications in diagnostic pathology, in peripheral blood and bone marrow transplantation, and in studies on the function and regulation of primitive haemopoietic stem cells. Antibody-coated magnetic microspheres (dynabeads) can be used to isolate these cells by positive selection...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Grimsley PG,Amos TA,Gordon MY,Greaves MF

    更新日期：1993-06-01 00:00:00

  • Ethnic and geographic diversity of chronic lymphocytic leukaemia.

    abstract：:East Asians, Asian Indians and Amerindians have a five to ten-fold lower age-adjusted incidence rate (AAIR) of chronic lymphocytic leukaemia (CLL) compared with persons of predominately European descent. The data we review suggest a genetic rather than environmental basis for this discordance. All these populations ar...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-01057-5

    authors： Yang S,Varghese AM,Sood N,Chiattone C,Akinola NO,Huang X,Gale RP

    更新日期：2020-10-19 00:00:00

  • Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

    abstract：:Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 in...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.243

    authors： Teh TC,Nguyen NY,Moujalled DM,Segal D,Pomilio G,Rijal S,Jabbour A,Cummins K,Lackovic K,Blombery P,Thompson E,Ekert PG,Lessene G,Glaser SP,Huang DCS,Roberts AW,Guthridge MA,Wei AH

    更新日期：2018-02-01 00:00:00

  • Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.

    abstract：:Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved long non-coding RNA (lncRNA). Overexpression of MALAT1 has been demonstrated to related to poor prognosis of multiple myeloma (MM) patients. Here, we demonstrated that MALAT1 plays important roles in MM DNA repair and cell death. We ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0104-2

    authors： Hu Y,Lin J,Fang H,Fang J,Li C,Chen W,Liu S,Ondrejka S,Gong Z,Reu F,Maciejewski J,Yi Q,Zhao JJ

    更新日期：2018-10-01 00:00:00

  • Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.

    abstract：:A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy. Fifty...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/sj.leu.2401843

    authors： Lengfelder E,Reichert A,Schoch C,Haase D,Haferlach T,Löffler H,Staib P,Heyll A,Seifarth W,Saussele S,Fonatsch C,Gassmann W,Ludwig WD,Hochhaus A,Beelen D,Aul C,Sauerland MC,Heinecke A,Hehlmann R,Wörmann B,Hiddemann

    更新日期：2000-08-01 00:00:00

  • Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Leukemia

    pub_type： 已发布勘误

    doi：10.1038/s41375-020-0782-4

    authors： Weisberg E,Meng C,Case A,Sattler M,Tiv HL,Gokhale PC,Buhrlage S,Wang J,Gray N,Stone R,Liu S,Bhagwat SV,Tiu RV,Adamia S,Griffin JD

    更新日期：2020-09-01 00:00:00

  • Leptin receptor, a surface marker for a subset of highly engrafting long-term functional hematopoietic stem cells.

    abstract：:The hematopoietic system is sustained by a rare population of hematopoietic stem cells (HSCs), which emerge during early embryonic development and then reside in the hypoxic niche of the adult bone marrow microenvironment. Although leptin receptor (Lepr)-expressing stromal cells are well-studied as critical regulators...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-01079-z

    authors： Trinh T,Ropa J,Aljoufi A,Cooper S,Sinn A,Srour EF,Broxmeyer HE

    更新日期：2020-11-07 00:00:00

  • Human stem cell factor (c-kit ligand) induces an autocrine loop of growth in a GM-CSF-dependent megakaryocytic leukemia cell line.

    abstract：:The M07e megakaryoblastic leukemia cell line is strictly dependent on either interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) for continuous growth. This study shows that recombinant human stem-cell factor (rhSCF) can completely replace these lymphokines in supporting the continued pro...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Kiss C,Cesano A,Zsebö KM,Clark SC,Santoli D

    更新日期：1993-02-01 00:00:00

  • Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

    abstract：:Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401851

    authors： Naito K,Takeshita A,Shigeno K,Nakamura S,Fujisawa S,Shinjo K,Yoshida H,Ohnishi K,Mori M,Terakawa S,Ohno R

    更新日期：2000-08-01 00:00:00

  • Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.

    abstract：:The long-term results in 130 patients with newly diagnosed acute myelogenous leukemia treated with continuous infusion high-dose ara-C (1.5 gm/m2/day x 4 days, CIHDAC) were compared with those in 264 patients treated in previous studies with standard dose ara-C (70-90 mg/m2/d x 7 days) plus either adriamycin (Ad-OAP),...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Ghaddar HM,Plunkett W,Kantarjian HM,Pierce S,Freireich EJ,Keating MJ,Estey EH

    更新日期：1994-08-01 00:00:00

  • Haplotype study of microsatellites flanking the t(15;17) breakpoint in acute promyelocytic leukemia patients from North Portugal.

    abstract：:A higher frequency of acute promyelocytic leukemia (APL) has been noted in countries of Southern Europe and among 'Latino' patients of the United States with acute myeloid leukemia (AML). In order to discover whether there is any genetic predisposition to the disease, we analyzed microsatellites flanking PML and RARal...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402525

    authors： Martins S,Trigo F,Azevedo L,Silva MJ,Guimaraes JE,Amorim A

    更新日期：2002-07-01 00:00:00